Private Asset Management Has Trimmed Iteris (ITI) Position By $44.31 Million; 7 Analysts Covering Natera, Inc. (NTRA)

Among 7 analysts covering Natera Inc (NASDAQ:NTRA), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Natera Inc has $25 highest and $12.0 lowest target. $16.14’s average target is 58.08% above currents $10.21 stock price. Natera Inc had 22 analyst reports since July 27, 2015 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Monday, October 23. The company was initiated on Monday, July 27 by Cowen & Co. On Monday, September 28 the stock rating was upgraded by Wedbush to “Outperform”. Wedbush maintained the shares of NTRA in report on Friday, August 28 with “Neutral” rating. On Friday, August 14 the stock rating was upgraded by Morgan Stanley to “Overweight”. The firm has “Buy” rating by Benchmark given on Monday, May 23. Morgan Stanley maintained the stock with “Overweight” rating in Monday, August 7 report. The stock has “Buy” rating by Piper Jaffray on Sunday, September 24. The stock of Natera, Inc. (NASDAQ:NTRA) has “Equal Weight” rating given on Monday, July 27 by Morgan Stanley. The stock of Natera, Inc. (NASDAQ:NTRA) has “Buy” rating given on Monday, October 23 by Robert W. Baird. See Natera, Inc. (NASDAQ:NTRA) latest ratings:

20/12/2017 Broker: Cowen & Co Rating: Buy New Target: $12.0 Maintain
14/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: $15.0 Maintain
23/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $16.0 Maintain
23/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $16.0 Maintain
06/10/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $13 New Target: $16 Maintain
24/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $18.0 Maintain
07/08/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $18 New Target: $13 Maintain
19/07/2017 Broker: Cowen & Co Rating: Buy New Target: $14.0000 Maintain

Private Asset Management Inc decreased Iteris Inc (ITI) stake by 99.33% reported in 2017Q3 SEC filing. Private Asset Management Inc sold 44,491 shares as Iteris Inc (ITI)’s stock rose 9.59%. The Private Asset Management Inc holds 298 shares with $297,000 value, down from 44,789 last quarter. Iteris Inc now has $248.86M valuation. The stock increased 3.41% or $0.25 during the last trading session, reaching $7.59. About 326,079 shares traded or 55.89% up from the average. Iteris, Inc. (NYSEMKT:ITI) has risen 136.03% since January 18, 2017 and is uptrending. It has outperformed by 119.33% the S&P500.

Analysts await Iteris, Inc. (NASDAQ:ITI) to report earnings on February, 8. They expect $-0.04 EPS, 0.00% or $0.00 from last year’s $-0.04 per share. After $-0.03 actual EPS reported by Iteris, Inc. for the previous quarter, Wall Street now forecasts 33.33% negative EPS growth.

Among 2 analysts covering Iteris Inc (NYSEMKT:ITI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Iteris Inc had 2 analyst reports since August 30, 2016 according to SRatingsIntel. As per Thursday, February 2, the company rating was initiated by Craig Hallum. The rating was initiated by Northland Capital on Tuesday, August 30 with “Outperform”.

The stock increased 3.44% or $0.34 during the last trading session, reaching $10.21. About 146,590 shares traded or 13.68% up from the average. Natera, Inc. (NASDAQ:NTRA) has declined 8.45% since January 18, 2017 and is downtrending. It has underperformed by 25.15% the S&P500.

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. The company has market cap of $548.98 million. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrierÂ’s children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. It currently has negative earnings. The firm also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father.